Therapeutics to Tackle Omicron Outbreak

References

• Chavda VP , KapadiaC , SoniSet al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy14(5), 351–371 (2022).
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS , DeOliveira T. New SARS-CoV-2 variants – clinical, public health, and vaccine implications. N. Engl. J. Med.384(19), 1866–1868 (2021).
   PubMed Web of Science ®Google Scholar
• Chavda VP , ApostolopoulosV. Global impact of delta plus variant and vaccination. Expert Rev. Vaccines21(5), 597–600 (2022).
   PubMed Web of Science ®Google Scholar
• Chavda VP , PatelAB , VaghasiyaDD. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol.94(7), 2986–3005 (2022).
   PubMed Web of Science ®Google Scholar
• Chavda VP , ApostolopoulosV. Omicron variant (B. 1.1. 529) of SARS-CoV-2: threat for the elderly?Maturitas158, 78–81 (2022).
   PubMed Web of Science ®Google Scholar
• Flemming A . Omicron, the great escape artist. Nat. Rev. Immunol.22(75), 1 (2022).
   PubMedGoogle Scholar
• Chavda VP , ApostolopoulosV. Is booster dose strategy sufficient for Omicron variant of SARS-CoV-2?Vaccines10(3), 367 (2022).
   PubMed Web of Science ®Google Scholar
• Rössler A , RieplerL , BanteD , Von LaerD , KimpelJ. SARS-CoV-2 Omicron variant neutralization in serum from vaccinated and convalescent persons. N. Engl. J. Med.386(7), 698–700 (2022).
   PubMed Web of Science ®Google Scholar
• Burki TK . Omicron variant and booster COVID-19 vaccines. Lancet Respir. Med.10(2), e17 (2022).
   PubMed Web of Science ®Google Scholar
• VanBlargan LA , ErricoJM , HalfmannPJet al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med.28, 490–495 (2022).
   PubMed Web of Science ®Google Scholar
• He X , HeC , HongW , ZhangK , WeiX. The challenges of COVID-19 Delta variant: prevention and vaccine development. MedComm2(4), 846–854 (2021).
   PubMedGoogle Scholar
• Wang B , GohYS , FongS-Wet al. Resistance of SARS-CoV-2 Delta variant to neutralization by BNT162b2-elicited antibodies in Asians. Lancet Reg. Health West Pac.15, 100276 (2021).
   PubMedGoogle Scholar
• Pouwels KB , PritchardE , MatthewsPCet al. Effect of Delta variant on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK. Nat. Med.27(12), 2127–2135 (2021).
   PubMed Web of Science ®Google Scholar
• Mistry P , BarmaniaF , MelletJ. SARS-CoV-2 variants, vaccines, and host immunity. Front. Immunol.12, 809244 (2022).
   PubMedGoogle Scholar
• Basu D , ChavdaVP , MehtaAA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr. Res. Pharmacol. Drug Discov.3, 100086 (2022).
   PubMedGoogle Scholar
• Liu L , IketaniS , GuoYet al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature602(7898), 676–681 (2022).
   PubMed Web of Science ®Google Scholar
• Bhattacharya M , SharmaAR , DhamaK , AgoramoorthyG , ChakrabortyC. Omicron variant (B. 1.1. 529) of SARS-CoV-2: understanding mutations in the genome, S-glycoprotein, and antibody-binding regions. Geroscience10.1007/s11357-022-00532-4 (2022) ( Epub ahead of print).
   Web of Science ®Google Scholar
• WHO (2022) . Weekly epidemiological update on COVID-19 – 1 February 2022. www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19—1-february-2022
   Google Scholar
• Lupala CS , YeY , ChenH , SuX-D , LiuH. Mutations on RBD of SARS-CoV-2 Omicron variant result in stronger binding to human ACE2 receptor. Biochem. Biophys. Res. Commun.590, 34–41 (2022).
   PubMed Web of Science ®Google Scholar
• Chavda VP , PatelAB , VaghasiyaDD. SARS-CoV-2 variants and vulnerability at the global level. J. Med. Virol.94(7), 2986–3005 (2022).
   PubMed Web of Science ®Google Scholar
• Chavda VP , BezbaruahR , AthalyeMet al. Replicating Viral Vector-Based Vaccines for COVID-19: Potential Avenue in Vaccination Arena. Viruses14(4), 759 (2022).
   PubMed Web of Science ®Google Scholar
• Zhao H , LuL , PengZet al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect.11(1), 277–283 (2022).
   PubMed Web of Science ®Google Scholar
• Harvey WT , CarabelliAM , JacksonBet al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol.19(7), 409–424 (2021).
   PubMed Web of Science ®Google Scholar
• Iketani S , LiuL , GuoYet al. Antibody evasion properties of SARS-CoV-2 Omicron sublineages. Nature604(7906), 553–556 (2022).
   PubMed Web of Science ®Google Scholar
• Dyer O . Covid-19: Omicron is causing more infections but fewer hospital admissions than delta, South African data show. BMJ375, n3104 (2021).
   PubMed Web of Science ®Google Scholar
• Mannar D , SavilleJW , ZhuXet al. SARS-CoV-2 Omicron variant: antibody evasion and cryo-EM structure of spike protein-ACE2 complex. Science375(6582), 760–764 (2022).
   PubMed Web of Science ®Google Scholar
• Zhang L , LiQ , LiangZet al. The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron. Emerg. Microbes Infect.11(1), 1–5 (2022).
   PubMed Web of Science ®Google Scholar
• Wang Y , MaY , XuYet al. Resistance of SARS-CoV-2 Omicron variant to convalescent and CoronaVac vaccine plasma. Emerg. Microbes Infect.11(1), 424–427 (2022).
   PubMed Web of Science ®Google Scholar
• Cheng SMS , MokCKP , LeungYWYet al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat. Med.28(3), 486–489 (2022).
   PubMed Web of Science ®Google Scholar
• Ma C , ChenX , MeiFet al. Drastic decline in sera neutralization against SARS-CoV-2 Omicron variant in Wuhan COVID-19 convalescents. Emerg. Microbes Infect.11(1), 567–572 (2022).
   PubMed Web of Science ®Google Scholar
• Gruell H , VanshyllaK , Tober-LauPet al. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med.28(3), 477–480 (2022).
   PubMed Web of Science ®Google Scholar
• Zhou W , HeP , LiJet al. Steep decline in binding capability of SARS-CoV-2 Omicron variant (B. 1.1. 529) RBD to the antibodies in early COVID-19 convalescent sera and inactivated vaccine sera. Viruses14(2), 335 (2022).
   PubMed Web of Science ®Google Scholar
• Carreño JM , AlshammaryH , TcheouJet al. Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. Nature602(7898), 682–688 (2022).
   PubMed Web of Science ®Google Scholar
• Shah M , WooHG. Omicron: a heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escapes approved COVID-19 therapeutic antibodies. Front. Immunol.12, 830527 (2022).
   PubMed Web of Science ®Google Scholar
• Park Y-J , MarcoAD , StarrTNet al. Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry. Science375(6579), 449–454 (2022).
   PubMed Web of Science ®Google Scholar
• Cameroni E , BowenJE , RosenLEet al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature602(7898), 664–670 (2022).
   PubMed Web of Science ®Google Scholar
• Cao Y , WangJ , JianFet al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature602(7898), 657–663 (2022).
   PubMed Web of Science ®Google Scholar
• Hoffmann M , KrügerN , SchulzSet al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell185(3), 447–456.e411 (2022).
   PubMed Web of Science ®Google Scholar
• Vanblargan LA , ErricoJM , HalfmannPJet al. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nat. Med.28(3), 490–495 (2022).
   PubMed Web of Science ®Google Scholar
• Takashita E , KinoshitaN , YamayoshiSet al. Efficacy of antiviral agents against the SARS-CoV-2 Omicron subvariant BA.2. N. Engl. J. Med.386(15), 1475–1477 (2022).
   PubMed Web of Science ®Google Scholar
• Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health, USA (2022). www.covid19treatmentguidelines.nih.gov/
   Google Scholar
• Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet399(10325), 665–676 (2022).
   PubMed Web of Science ®Google Scholar
• Self WH , SandkovskyU , ReillyCSet al. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial. Lancet Infect. Dis.22(5), 622–635 (2022).
   PubMed Web of Science ®Google Scholar
• Dougan M , NirulaA , AzizadMet al. Bamlanivimab plus etesevimab in mild or moderate Covid-19. N. Engl. J. Med.385(15), 1382–1392 (2021).
   PubMed Web of Science ®Google Scholar
• Chavda VP , VoraLK , PandyaAK , PatravaleVB. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov. Today26(11), 2619–2636 (2021).
   PubMed Web of Science ®Google Scholar
• Chavda VP , PandyaA , KypreosE , PatravaleV , ApostolopoulosV. Chlamydia trachomatis: quest for an eye-opening vaccine breakthrough. Expert Rev. Vaccines10.1080/14760584.2022.2061461 (2022) ( Epub ahead of print).
   Web of Science ®Google Scholar